222 related articles for article (PubMed ID: 23088328)
1. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
Kunøe N; Lobmaier P; Ngo H; Hulse G
Br J Clin Pharmacol; 2014 Feb; 77(2):264-71. PubMed ID: 23088328
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
Lobmaier PP; Kunøe N; Gossop M; Waal H
CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
[TBL] [Abstract][Full Text] [Related]
3. Long-acting depot formulations of naltrexone for heroin dependence: a review.
Krupitsky EM; Blokhina EA
Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
[TBL] [Abstract][Full Text] [Related]
4. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.
Hulse GK; Tait RJ; Comer SD; Sullivan MA; Jacobs IG; Arnold-Reed D
Drug Alcohol Depend; 2005 Sep; 79(3):351-7. PubMed ID: 15899557
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
Jones HE; Chisolm MS; Jansson LM; Terplan M
Addiction; 2013 Feb; 108(2):255-6. PubMed ID: 23331881
[No Abstract] [Full Text] [Related]
6. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
8. Retention in naltrexone implant treatment for opioid dependence.
Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen O; Waal H
Drug Alcohol Depend; 2010 Sep; 111(1-2):166-9. PubMed ID: 20570059
[TBL] [Abstract][Full Text] [Related]
9. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.
Krupitsky E; Zvartau E; Woody G
Curr Psychiatry Rep; 2010 Oct; 12(5):448-53. PubMed ID: 20640538
[TBL] [Abstract][Full Text] [Related]
10. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
11. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
12. Sustained-release naltrexone for opioid dependence.
Lobmaier P; Kornør H; Kunøe N; Bjørndal A
Cochrane Database Syst Rev; 2008 Apr; (2):CD006140. PubMed ID: 18425938
[TBL] [Abstract][Full Text] [Related]
13. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
14. Challenges to antagonist blockade during sustained-release naltrexone treatment.
Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Gossop M; Hegstad S; Kristensen Ø; Waal H
Addiction; 2010 Sep; 105(9):1633-9. PubMed ID: 20707781
[TBL] [Abstract][Full Text] [Related]
15. A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.
Sibai M; Mishlen K; Nunes EV; Levin FR; Mariani JJ; Bisaga A
Am J Drug Alcohol Abuse; 2020 May; 46(3):289-296. PubMed ID: 31860366
[TBL] [Abstract][Full Text] [Related]
16. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
17. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
Gerra G; Fantoma A; Zaimovic A
J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
[TBL] [Abstract][Full Text] [Related]
19. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
